Find stats on top websites
Industry Landscape
The healthcare AI consulting industry is rapidly expanding, driven by the need for efficiency, improved patient outcomes, and regulatory compliance. Organizations are actively seeking partners to integrate AI, especially GenAI, into operations, from patient engagement to drug discovery, while prioritizing data privacy and security like HIPAA. The focus is on custom, end-to-end solutions that enhance human intellect rather than replace it.
Total Assets Under Management (AUM)
US Healthcare Artificial Intelligence Market Size in United States
~30.1 Billion USD (2023)
(38.5% CAGR)
Growth is driven by: - Increasing adoption of AI in drug discovery and development. - Rising demand for AI-powered solutions in healthcare. - Emphasis on improving patient outcomes and operational efficiency.
Total Addressable Market
30.1 Billion USD
Market Growth Stage
Pace of Market Growth
Emerging Technologies
Generative AI (GenAI) Advancements
Continuous breakthroughs in large language models (LLMs) and diffusion models are enabling more sophisticated and accurate content generation, automation of complex tasks, and hyper-personalization in healthcare.
Federated Learning & Privacy-Preserving AI
This technology allows AI models to be trained on decentralized datasets at their source, enhancing data privacy and security by minimizing the need for direct data sharing, crucial for sensitive healthcare information.
Digital Twins in Healthcare
The creation of virtual replicas of organs, patients, or even entire healthcare systems enables predictive modeling, personalized treatment plans, and optimized operational efficiency without risk to real subjects.
Impactful Policy Frameworks
HHS Final Rule on HIPAA Privacy Rule Changes (2024)
The U.S. Department of Health and Human Services (HHS) has proposed updates to the HIPAA Privacy Rule to support reproductive healthcare access, clarify permitted disclosures, and strengthen patient rights regarding protected health information (PHI).
This policy will require BigRio to ensure its AI solutions and data handling practices are rigorously compliant with updated privacy standards, particularly when dealing with sensitive health data and interoperability, potentially necessitating adjustments to data flows and access controls.
Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (October 2023)
This broad executive order directs federal agencies to establish new standards for AI safety and security, protect privacy, advance equity and civil rights, stand up for consumers, workers, and innovators, and promote American leadership in AI.
BigRio will need to ensure its AI development and deployment adhere to emerging federal safety, security, and ethical guidelines, potentially requiring new internal protocols for bias detection, transparency, and data governance for its healthcare AI solutions.
FDA's Guidance on Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) (2021, evolving)
The FDA provides a framework for regulating AI/ML-based software that meets the definition of a medical device, focusing on a 'Total Product Lifecycle' approach that emphasizes ongoing performance monitoring and transparency.
For any of BigRio's AI solutions that qualify as SaMD (e.g., diagnostic AI), strict adherence to FDA pre-market and post-market requirements for safety, efficacy, and performance will be crucial, potentially influencing development cycles and validation processes.
Transform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
